Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Chemotherapeutic agents give rise to numerous well described adverse effects that may
affect the skin, hair, mucous membranes, or nails. The mucocutaneous effects of …

Importance A randomized clinical trial is needed to determine whether the second-
generation Abl–tyrosine kinase inhibitor dasatinib is more effective than the first-generation …

Purpose The causes of the aggressive nature of BCR-ABL1–positive adult acute
lymphoblastic leukemia (ALL) are unknown. To identify, at the submicroscopic level …

The specificities of nine approved tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib,
gefitinib, erlotinib, lapatinib, sorafenib, sunitinib, and pazopanib) were determined by activity …

We investigated the effects of nilotinib plus multiagent chemotherapy, followed by
consolidation/maintenance or allogeneic hematopoietic cell transplantation (allo-HCT) for …

In the past decade, the available treatments for patients with acute lymphoblastic leukemia
(ALL) have rapidly expanded, in parallel with an increased understanding of the genomic …

Major advances in the use of carrier vehicles delivering pharmacologic agents and enzymes
to sites of disease have occurred over the past 10 years. This review focuses on the …

Protein degradation is a promising strategy for drug development. Proteolysis-targeting
chimeras (PROTACs) hijacking the E3 ligase cereblon (CRBN) exhibit enormous potential …

Imatinib mesylate is the first of a novel group of drugs that specifically target protein tyrosine
kinases, which are central to the pathogenesis of human cancer. It has been approved for …